Corticosteroids in combination therapy for multiple sclerosis

The Lancet Neurology

Volumn 8, Issue 6, 2009, Pages 502-503

  Cohen, Jeffrey A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; NATALIZUMAB; PREDNISOLONE;

CLINICAL TRIAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GASTROINTESTINAL TOXICITY; HUMAN; INSOMNIA; LETTER; LOW DRUG DOSE; MEDICAL LITERATURE; MULTIPLE SCLEROSIS; PATHOGENESIS; PRIORITY JOURNAL; RECURRENT DISEASE; RESTLESSNESS; TASTE DISORDER;

ADRENAL CORTEX HORMONES; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-BETA; MULTIPLE SCLEROSIS;

EID: 65549152778     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(09)70089-4     Document Type: Letter

References (5)

1. Cohen J.A., and Confavreux C. Combination therapy in multiple sclerosis. In: Cohen J.A., and Rudick R.A. (Eds). Multiple sclerosis therapeutics. 3rd edn. (2007), Informa Healthcare, London 681-697
2. Sorensen P.S., Mellgren S.I., Svenningsson A., et al. Nordic trial of oral methylprednisolone as add-on therapy to interferon beta-1a for treatment of relapsing-remitting multiple sclerosis (NORMIMS study): randomised controlled trial. Lancet Neurol (2009) 10.1016/S1474-4422(09)70085-7 published online April 30.
3. Cohen J.A., Imrey P.B., Calabresi P.A., et al. Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS. Neurology 72 (2009) 535-541
4. Zivadinov R., Rudick R.A., De Masi R., et al. Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology 57 (2001) 1239-1247
5. Ravnborg M, Sorensen PS, Andersson ML, et al. A multi-centre, double blind, randomized, placebo controlled, parallel group trial investigating methylprednisolone (MP) as add-on to interferon beta-1a for the treatment of relapsing-remitting multiple sclerosis. Presented at the American Academy of Neurology 2009 Annual Meeting. Seattle, WA, USA. April, 2009. Abstract LB3.002.